Milestones
Health and medical research, and its translation into evidence-based clinical practice, public health policy and health services delivery, are vital for the continued advancement of human health and wellbeing. As Sri Lanka’s pioneering clinical trials management company, RemediumOne plays a critical role in supporting the broad range of research activities needed to address current and future health challenges in partnership with key stakeholders in the country and collaborators around the world.
Sri Lanka’s clinical research environment, like any other evolving market, is expected to change dramatically over the coming years. However, our overriding philosophy of placing clients and quality at the heart of everything we do will remain unchanged. As we head past our 10th anniversary towards the future, we will continue to transform ourselves and take on new challenges with the aim of creating a solid operating platform that can deliver consistent results under all circumstances.
As an innovation-led organization focused on providing high-quality clinical trial management services, we have combined our inherent strengths in project coordination and implementation with the expertise of our academic partner to successfully conduct a diverse portfolio of hospital- and community-based clinical research projects. The search for excellence by our RemediumOne team, who have never been afraid of change or taking on new challenges, is at the heart of our success. We believe our human capital input continues to make the biggest difference in delivering world-class results, consistently across all projects, in the varied therapeutic areas we work in.
Looking ahead, we are entering an era in which conventional wisdom will be increasingly challenged and the healthcare industry will see considerable changes in both treatment design and delivery. No matter what the future holds, RemediumOne will expand our focus with an eye on helping solve the issues of our research partners while continuing to be relevant to society.